IR Information
IR Information
News Release
News release
-
2023.12.25
Announcement of Preliminary Results of Phase II Clinical Trial of PC-SOD
(155KB)
-
2023.12.21
Semi-annual report for the 22nd period has been submitted
(396KB)
-
2023.12.12
Announcement of Phase III Clinical Trial Results for LT-5001
(170KB)
-
2023.12.05
Announcement of Renewal of Business Collaboration Agreement with Sino Biopharmaceutical Co., Ltd.
(167KB)
-
2023.12.05
Report on Participation in BIO Europe 2023 Munich
(563KB)
Financial Information
Disclosure
Financial Results
| 21st Fiscal Period (Results for March 2023) | |
|---|---|
| Net sales (Thousands of yen) | 15,271 |
| Operating income (thousand yen) | 81,000 |
| Net income (thousand yen) | 70,254 |
| Net assets (Thousands of yen) | 4,002,480 |
| Total assets (Thousands of yen) | 4,214,922 |
| Equity ratio (%) | 94.9 |
Business Report
Business report
21th Term
Business Overview
(485KB)
20th Term
Business Overview
(568KB)
19th Term
Business Overview
(595KB)
18th Term
Business Overview
(527KB)
17th Term
Business Overview
(521KB)
